Loading...
•
Jun 30, 2023
Arcutis Q2 2023 Earnings Report
Arcutis's financial performance and business progress were discussed.
Key Takeaways
Arcutis Biotherapeutics reported total revenues of $5.2 million for Q2 2023, with ZORYVE contributing $4.8 million, a 72% increase from Q1 2023. The company's commercial coverage expanded to over 130 million commercial lives in the US, and ZORYVE was launched in Canada. Arcutis had approximately $270 million in cash, cash equivalents, and marketable securities as of June 30, 2023.
Total revenues reached $5.2 million in Q2 2023.
ZORYVE net product revenues were $4.8 million, a 72% increase compared to Q1 2023.
Commercial payer coverage for ZORYVE expanded to over 130 million lives in the US.
ZORYVE was launched in Canada in June 2023.
Forward Guidance
Arcutis will continue to invest to fuel the next leg of the psoriasis launch, while also preparing for the upcoming launches in seborrheic dermatitis and atopic dermatitis in 2024, upon their respective anticipated U.S. Food and Drug Administration (FDA) approvals.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...